Phoenix Financial Ltd. Invests $542,000 in Illumina, Inc. $ILMN

Phoenix Financial Ltd. bought a new position in Illumina, Inc. (NASDAQ:ILMN) during the 3rd quarter, Holdings Channel reports. The fund bought 5,704 shares of the life sciences company’s stock, valued at approximately $542,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Parkside Financial Bank & Trust lifted its holdings in Illumina by 65.7% in the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after buying an additional 115 shares during the period. Quent Capital LLC purchased a new position in shares of Illumina during the third quarter valued at approximately $29,000. Cullen Frost Bankers Inc. bought a new position in shares of Illumina during the second quarter valued at approximately $41,000. NewSquare Capital LLC lifted its stake in Illumina by 604.9% in the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock worth $41,000 after acquiring an additional 369 shares during the period. Finally, Mather Group LLC. bought a new stake in Illumina in the third quarter valued at $46,000. Institutional investors own 89.42% of the company’s stock.

Insider Activity at Illumina

In other Illumina news, insider Scott M. Davies sold 323 shares of the business’s stock in a transaction on Friday, December 12th. The stock was sold at an average price of $136.09, for a total value of $43,957.07. Following the sale, the insider directly owned 17,887 shares of the company’s stock, valued at approximately $2,434,241.83. The trade was a 1.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Scott Gottlieb bought 500 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was bought at an average cost of $122.13 per share, for a total transaction of $61,065.00. Following the completion of the purchase, the director owned 12,523 shares of the company’s stock, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on ILMN shares. Stifel Nicolaus boosted their price objective on shares of Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. TD Cowen reiterated a “hold” rating on shares of Illumina in a research report on Wednesday, January 7th. JPMorgan Chase & Co. increased their price target on shares of Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. UBS Group lifted their price objective on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research report on Friday, October 31st. Finally, Robert W. Baird set a $109.00 target price on Illumina in a report on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $127.18.

Illumina Trading Down 1.5%

Shares of NASDAQ ILMN opened at $149.86 on Thursday. The stock has a market cap of $22.90 billion, a P/E ratio of 33.60, a price-to-earnings-growth ratio of 2.52 and a beta of 1.41. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $155.53. The firm has a 50-day moving average of $137.06 and a 200 day moving average of $114.34.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, October 30th. The life sciences company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.16 by $0.18. Illumina had a net margin of 16.40% and a return on equity of 29.21%. The business had revenue of $1.08 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter last year, the firm earned $1.14 earnings per share. The business’s revenue for the quarter was up .4% on a year-over-year basis. As a group, sell-side analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.